The proportion of cases with unfavorable outcomes ranged from 9.7 to 51.3% and WGS detected several mutations conferring clinically relevant drug resistance, such as mutations in the gyrA for high-level fluoroquinolone resistance, rrs for high-level kanamycin resistance, rpoB Ile491Phe conferring rifampicin resistance harbored in MDR-TB, and ethA for prothionamide resistance, which were all associated with poor outcomes. This evidence concerns the gene SCN9A and tuberculosis.